Casi Pharmaceuticals Stock News

Each day, Benzinga takes a look back at a notable market-related moment that occurred on this date. What Happened? On May 3, 1998, a front-page New York Times report suggested EntreMed was two years a

According to a Bloomberg report, U.S. regulators could reportedly have full access to auditing reports from most of the 200-plus China-based companies listed in New York in mid-2022. In the drafting

CASI Pharmaceuticals, Inc. (CASI) CEO Wei-Wu He on Q4 2021 Results - Earnings Call Transcript

CASI Pharmaceuticals (CASI) renewed an exclusive distribution agreement under which China Resources Pharmaceutical Commercial Group International Trading Co

CASI Pharmaceuticals (CASI) expects EVOMELA revenue of ~$9.12M for Q4 and ~$30M (+100% Y/Y) for FY ended Dec.31,2021 which exceeds the estimated $27M guidance.Analysts consensus…

ROCKVILLE, Md. and BEIJING, Feb. 16, 2022 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced preliminary and unaudited revenues for the…

CASI Pharmaceuticals (CASI) announced that the FDA had awarded its partner BioInvent International, the Orphan Drug Designation (ODD) for an investigational therapy targeted at

CASI Pharmaceuticals <> said the U.S. Food and Drug Administration ((FDA)) has granted orphan drug designation to its partner Juventas Cell Therapy''s medicine CNCT19 to

CASI Pharmaceuticals Inc (CASI) shares closed today at 0.5% above its 52 week low of $0.72, giving the company a market cap of $101M. The stock is currently down 9.7% year-to-date, down 78.3% over the past 12 months, and down 42.2% over the past five years. This week, the Dow Jones Industrial Average fell 0.9%, and the S&P 500 fell 0.3%. Trading Activity Trading volume this week was 184.2% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.2. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought.The stock closed at 5.0% lower than its 5-day moving average, 10.8% lower than its 20-day moving average, and 29.9% lower than its 90-day moving average. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -14.5% The company's stock price performance over the past 12 months lags the peer average by 154.6% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

CASI Pharmaceuticals, Inc. (NASDAQ:CASI) with the stream of 2.18% also noticed, India Gran Tierra Energy Inc. (AMEX:GTE) encountered a rapid change of -0.07% in the last hour of Thursdays trading The post Hilly Stock: CASI Pharmaceuticals, Inc. (NASDAQ:CASI), Gran Tierra Energy Inc. (AMEX:GTE) appeared first on Stocks Equity .

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Merck Announces Publication Of Positive Data From Late-Stage Study Of Oral COVID-19 Antiviral Treatmen

ROCKVILLE, Md. and BEIJING, Dec. 17, 2021 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), (the "Company" or "CASI"), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced that its board of

CASI Pharmaceuticals (NASDAQ:CASI) and Valneva (NASDAQ:VALN) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, dividends, earnings and risk. Analyst Recommendations This is a summary of recent ratings and price targets for CASI Pharmaceuticals and Valneva, [] The post Head to Head Comparison: Valneva (NASDAQ:VALN) versus CASI Pharmaceuticals (NASDAQ:CASI) appeared first on ETF Daily News .